TABLE 2

Pharmacodynamics and pharmacokinetics of the three treatment groups

Means ± SD
CVs (%)
Insulin detemirNPH insulinInsulin glargineInsulin detemirNPH insulinInsulin glargine
Pharmacodynamics
 GIR-AUC(0–12 h) (mg/kg)1,130 ± 3121,280 ± 559886 ± 3252759*46*
 GIR-AUC(0–24 h) (mg/kg)1,703 ± 4901,923 ± 7651,474 ± 4982768*48*
 GIR-AUC(2–24 h) (mg/kg)1,608 ± 4591,831 ± 7441,377 ± 4822777*66*
 GIRmax (mg · kg−1 · min−1)2.3 ± 0.52.7 ± 1.11.8 ± 0.62346*36*
Pharmacokinetics
 INS-AUC(0–12 h) (nmol · min−1 · l−1)1,295 ± 20175 ± 2046 ± 16152634
 INS-AUC(0–∞) (nmol · min−1 · l−1)2,355 ± 323162 ± 48128 ± 42142833
Cmax (pmol/l)2,865 ± 626147 ± 4099 ± 33182434
  • *

    * P < 0.001 vs. insulin detemir.